Trial Profile
A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AGTC 0106 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions
- Sponsors Applied Genetic Technologies Corporation
- 08 Jun 2017 According to an Applied Genetic Technologies Corporation media release, results from this study were published in Molecular Therapy.
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 20 Jan 2016 According to an Applied Genetic Technologies Corporation media release, results were published online in the journal Human Gene Therapy and will appear in the January 2016 print issue.